Working… Menu
Trial record 32 of 36 for:    Acerta Pharma

Acalabrutinib Plus RICE for Relapsed/Refractory DLBCL

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03736616
Recruitment Status : Not yet recruiting
First Posted : November 9, 2018
Last Update Posted : November 14, 2018
Acerta Pharma BV
Information provided by (Responsible Party):
Swedish Medical Center

No Study Results Posted on for this Study
Recruitment Status : Not yet recruiting
Estimated Primary Completion Date : September 2021
Estimated Study Completion Date : September 2022